UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

Annals of oncology, 2017-09, Vol.28 (9), p.2225-2232

2017

Volltextzugriff (PDF)

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

Journal of translational medicine, 2015-06, Vol.13 (1), p.204-204, Article 204

2015

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi28

2017

Volltextzugriff (PDF)

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer

Annals of oncology, 2018-04, Vol.29 (4), p.881-887

2018

Volltextzugriff (PDF)

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Annals of oncology, 2012-06, Vol.23 (6), p.1436-1441

2012

Volltextzugriff (PDF)

Five Year Results With 3-D Conformal Radiation Therapy to Deliver Partial-Breast Irradiation Consisting of 40 Gy in 10 Daily Fractions

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E33-E33

2015

Volltextzugriff (PDF)

Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S769-S769

2014

Volltextzugriff (PDF)

PO-0675: Radical radiotherapy in ologometastatic breast cancer patients

Radiotherapy and oncology, 2016-04, Vol.119, p.S315-S315

2016

Volltextzugriff (PDF)

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.122-137

2018

Volltextzugriff (PDF)

Cancer and aging: are there any differences in the information needs of elderly and younger patients? Results from an Italian observational study

Annals of oncology, 2005-12, Vol.16 (12), p.1982-1983

2005

Volltextzugriff (PDF)

Fatigue in cancer patients receiving chemotherapy: an analysis of published studies

Annals of oncology, 2004-10, Vol.15 (10), p.1576-1576

2004

Volltextzugriff (PDF)

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Volltextzugriff (PDF)

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

The Lancet (British edition), 2023-02, Vol.401 (10374), p.347-356

2023

Volltextzugriff (PDF)

416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study

Annals of oncology, 2024-09, Vol.35, p.S395-S395

2024

Volltextzugriff (PDF)

380P Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)

Annals of oncology, 2024-09, Vol.35, p.S378-S378

2024

Volltextzugriff (PDF)

242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach

Annals of oncology, 2022-09, Vol.33, p.S648

2022

Volltextzugriff (PDF)

Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors

Critical reviews in oncology/hematology, 2005-02, Vol.53 (2), p.125-131

2005

Volltextzugriff (PDF)

458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey

Annals of oncology, 2023-10, Vol.34, p.S373-S374

2023

Volltextzugriff (PDF)

249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study

Annals of oncology, 2022-09, Vol.33, p.S650

2022

Volltextzugriff (PDF)

Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days

Lung cancer (Amsterdam, Netherlands), 2005-09, Vol.49 (3), p.417-418

2005

Volltextzugriff (PDF)

415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)

Annals of oncology, 2023-10, Vol.34, p.S357-S357

2023

Volltextzugriff (PDF)

162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial

Annals of oncology, 2020-09, Vol.31, p.S304-S305

2020

Volltextzugriff (PDF)

129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial

Annals of oncology, 2021-09, Vol.32, p.S414-S414

2021

Volltextzugriff (PDF)

Use of sorafenib in elderly patients (EP) affected by metastatic renal cell carcinoma (RCC) according to the Comprehensive Geriatric Assessment (CGA)

Critical reviews in oncology/hematology, 2008-10, Vol.68, p.S46-S46

2008

Volltextzugriff (PDF)

Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma

Annals of oncology, 2006-08, Vol.17 (8), p.1335-1336

2006

Volltextzugriff (PDF)

1 – 25 von 229

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(20)
Journal Of Clinical Oncology
(20)
Cancer Research
(11)
Zdravniški Vestnik
(10)
Critical Reviews In Oncology/hematology
(8)
Slovenska Pediatrija
(8)
Tumori
(8)
Child's Nervous System
(6)
World Journal Of Clinical Cases
(5)
Codas
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Five Year Results With 3-D Conformal Radiation Therapy to Deliver Partial-Breast Irradiation Consisting of 40 Gy in 10 Daily Fractions

Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers

PO-0675: Radical radiotherapy in ologometastatic breast cancer patients

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Cancer and aging: are there any differences in the information needs of elderly and younger patients? Results from an Italian observational study

Fatigue in cancer patients receiving chemotherapy: an analysis of published studies

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study

380P Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)

242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach

Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors

458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey

249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study

Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days

415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)

162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial

129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial

Use of sorafenib in elderly patients (EP) affected by metastatic renal cell carcinoma (RCC) according to the Comprehensive Geriatric Assessment (CGA)

Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma

Suchergebnisse filtern